Monopex (Dexamethasone Phosphate)

Dexamethasone phosphate, the active ingredient in Monopex, is a glucocorticoid presented as a sterile ophthalmic solution for ocular use. It reduces inflammation and suppresses immune responses in the eye, helping manage conditions such as postoperative inflammation, uveitis and allergic conjunctivitis.

GNH USA supplies Monopex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Monopex, a glucocorticoid, is used to treat inflammatory eye disorders.

Ocular inflammation: alleviates swelling, redness and pain in the eye. Post‑operative inflammation: controls inflammatory response after eye surgery. Uveitis: reduces intra‑ocular inflammation and prevents tissue damage. Allergic conjunctivitis: diminishes allergic eye irritation and swelling.

Adverse ocular and systemic reactions may occur with the use of Monopex.

Common Side Effects: - Eye irritation or burning sensation. - Temporary blurred vision. - Increased intra‑ocular pressure. - Mild headache. - Conjunctival hyperemia.

Serious or Rare Side Effects: - Secondary ocular infection. - Severe allergic reaction (anaphylaxis). - Persistent elevation of intra‑ocular pressure leading to glaucoma. - Cataract formation with prolonged use.

Before prescribing Monopex, clinicians should consider the following precautions.

- Monitor intra‑ocular pressure: check pressure regularly during therapy. - Avoid in active ocular infections: do not use if viral or fungal eye infection is present. - Use with caution in diabetic patients: systemic absorption may affect glucose control. - Limit duration of therapy: prolonged use increases risk of cataract and glaucoma. - Discontinue if severe allergic reaction occurs: stop treatment immediately. - Store at room temperature: keep in the original container, protect from light and moisture.

Monopex may interact with other medications affecting steroid metabolism or ocular physiology.

Major Interactions (Avoid): - Systemic corticosteroids: additive immunosuppression and increased risk of systemic side effects. - CYP3A4 inhibitors (e.g., ketoconazole): may raise intra‑ocular steroid levels.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) eye drops: potential for delayed wound healing. - Antihistamine eye drops: may reduce anti‑inflammatory efficacy. - Anticholinergic agents: possible increase in intra‑ocular pressure.